Spinoff stocks are the newly listed companies created when a parent carves out a division and hands the shares to its own holders, and as a group they have a long record of beating the broader market in the years after separation. The harder part is not knowing that the category works; it is figuring out whether a specific spinoff is one of the winners or one of the losers that the average hides. That judgment, not the category fact, is where the money is made or lost.
What Makes a Spinoff Work
The edge comes from two engines that run on different timelines. The first is focus: a unit freed from its parent gets its own management, its own incentives, and its own capital discipline, and the improvement in decision-making shows up over quarters and years. The second is mechanical: the forced selling of orphaned shares in the first weeks depresses the opening price, and the recovery as real investors build positions is a one-time event. Both are real, both are documented, and both are why the category has historically beaten the market.
The timing engine is the one that matters for the ISO pitch. Gabe Marshank’s Market Maven presentation frames 2026’s heavy IPO calendar and its “aftershock” as the reason spinoffs are attractive right now: a flood of new listings absorbs attention and capital, while carve-outs arrive without a roadshow and without demand. The “aftershock” framing is a story about when, layered on top of the standard story about why. For the full academic picture behind that why, see our corporate spinoffs explainer.
How to Evaluate a Spinoff
The checklist is the same one you would run on any company, with a spinoff twist. Start with the business itself: does it earn real cash flow, or is it being spun off because the parent wanted to offload a problem? Check the balance sheet the parent hands it, because carve-outs sometimes inherit more debt than is obvious at first glance. Look at who is selling early and whether the forced selling is still in progress or already exhausted. And weigh the size, because the orphan discount is strongest in smaller, less-followed names and weaker in large, well-covered ones.
The two names teased in the pitch illustrate the range. Solstice Advanced Materials carries a market value near $10 billion, while Versigent is closer to $2.95 billion. The smaller name sits in the size range where the orphan effect historically bites hardest, while the larger one is past the point where a carve-out goes unnoticed. That single difference changes the risk profile of the two picks more than most investors realize. Our Solstice profile and Versigent profile walk through each in detail.
The Bottom Line
Spinoff stocks earn their reputation as a group. The focus and orphan-selling effects are real, and the historical outperformance is one of the most consistent results in the empirical finance literature. Where the pitch gets harder to defend is the leap from category to specific names, especially at today’s prices. A category edge is an input to stock selection, not a substitute for it, and the size, the balance sheet, and the price you actually pay decide more than any historical chart does.
The Size and Liquidity Trap
The orphan discount does not distribute itself evenly. It concentrates in the smallest carve-outs, where the forced selling is large relative to the float and where almost nobody is paying attention yet. A micro-cap spinoff can fall 20% or more in its first weeks on volume that a large institutional holder would find meaningless, because there simply are not many natural buyers on the other side. That is also why the recovery in small names can be sharper when it comes: a little buying moves a small float a lot.
The same fact cuts both ways. Small spinoffs are illiquid, and illiquidity is a real cost. Wide bid-ask spreads, thin daily volume, and the risk that you cannot exit at a fair price when you want to are all part of owning a freshly listed micro-cap. The size range also means a smaller cushion against a bad quarter, because a single disappointing result moves a small company far more than it moves a $10 billion one.
This is where the two teased names separate cleanly. Versigent, near $2.95 billion, sits in the zone where the discount can be meaningful but the stock is still small enough to be volatile and thinly traded. Solstice Advanced Materials, near $10 billion, is past the point where a carve-out goes unnoticed and past the point where the orphan discount runs deep. Neither is automatically better; they are different trades with different liquidity profiles, and the pitch’s one-size framing does not capture that.
Ready to see the research? Click here to access Gabe Marshank’s report.
NewsletterVetter is an independent publication. We receive compensation from some of the services we review through affiliate links. Nothing on this site is investment advice. Always do your own research.